Decompensated Cirrhosis Epidemiology Forecast/Research Report 2019-2021 & 2022-2032: Focus on United States, Germany, Spain, Italy, France, United Kingdom, and Japan – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Decompensated Cirrhosis – Epidemiology Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering.

This “Decompensated Cirrhosis – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Decompensated Cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Decompensated Cirrhosis Epidemiology Perspective

The Decompensated Cirrhosis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Decompensated Cirrhosis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM.

The Decompensated Cirrhosis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Decompensated Cirrhosis Detailed Epidemiology Segmentation

The Decompensated Cirrhosis epidemiology covered in the report provides historical as well as forecasted Decompensated Cirrhosis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The Decompensated Cirrhosis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Decompensated Cirrhosis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Decompensated Cirrhosis Epidemiology Report and Model provide an overview of the global trends of Decompensated Cirrhosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Decompensated Cirrhosis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Decompensated Cirrhosis
• The report provides the segmentation of the Decompensated Cirrhosis epidemiology

Report Highlights

• 11-year Forecast of Decompensated Cirrhosis epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Decompensated Cirrhosis
• Cases of Decompensated Cirrhosis by Mutation Types
• Decompensated Cirrhosis Cases associated with Clinical Manifestations

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Key Topics Covered:

1. Key Insights

2. Executive Summary of Decompensated Cirrhosis

3. Decompensated Cirrhosis: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Decompensated Cirrhosis Epidemiology Scenario in the 7MM (2019-2032)

5.4. United States Epidemiology

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.2. France Epidemiology

5.5.3. Italy Epidemiology

5.5.4. Spain Epidemiology

5.5.5. United Kingdom Epidemiology

5.6. Japan Epidemiology

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Decompensated Cirrhosis Treatment and Management

6.2. Decompensated Cirrhosis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/5czflb

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900